Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: Analysis of MRI responses to treatment and correlation with NAb

Multiple Sclerosis

Volumn 12, Issue 1, 2006, Pages 72-76

  Barbero, Pierangelo ^a,b   Bergui, M ^a   Versino, E ^a   Ricci, A ^a   Zhong, J J ^a   Ferrero, B ^a   Clerico, M ^a   Pipieri, A ^a   Verdun, E ^a   Giordano, L ^a   Durelli, L ^a   Cussi, A ^a   Genesia, M L ^a   Festa, E ^a   Contessa, G ^a   Ghezzi, A ^a   Zaffaroni, M ^a   Cavallo, R ^a   Salvi, F ^a   Scandellari, C ^a   Stecchi, S ^a   Benedetti, M G ^c   Moretto, G ^c   Fiumani, A ^c   Montanari, E ^a   Ludovico, L ^a   Pesce, I ^a   Tartaglione, A ^a   Parodi, R C ^a   Nobile, M ^a   Morino, U ^a   Giuliani, F ^a   Pucci, E ^a   Cartechini, E ^a   Taus, C ^d   Urciuoli, R ^a   Giulietti, M ^a   Motti, L ^a   Meola, G ^a   Radice, S ^a   Robotti, M ^a   Toso, V ^a   Bortolon, F ^a   Milanise, A ^a   La Mantia, L ^a   Morgando, E ^a   Di Sapio, A ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Burden of disease (BOD); Interferon beta dose; Interferon beta 1a; Interferon beta 1b; Magnetic resonance imaging (MRI); MRI active lesions; Neutralizing antibodies to interferon beta (NAb); Relapsing remitting multiple sclerosis (RRMS)

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; RELAPSE; REMISSION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; ANTIBODY FORMATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 31644439703     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1247oa     Document Type: Article

References (10)

1. The IFN-BETA Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing - remitting multiple sclerosis. Clinical results of a multicenter, randomized, double-bind, placebo-controlled trial. Neurology 1993; 43: 655-61.
2. The PRISMS Study Group. Randomized, double-blind placebo-controlled study of interferon beta-1a in relapsing - remitting multiple sclerosis: clinical results. Lancet 1998; 352: 1498-504.
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-92.
4. Panitch H. Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P et al. EVIDENCE Study Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-506.
5. Zhao GJ, Koopmans RA, Li DK, Bedell L, Paty DW. Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the NIS Study Group. Neurology 2000; 54: 200-206.
6. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39: 6-16.
7. Molyneux PD, Filippi M, Barkhof F, Gasperini C, Yousry TA, Truyen L et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998; 43: 332-39.
8. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M et al. Development of neutralizing antibodies in patients with relapsing remitting multiple sclerosis treated with IFN beta-1a. J Interferon Cytokine Res 1998; 18: 45-50.
9. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, and the Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60.
10. Rosenthal R. Parametric measures of effect size. In Copper H, Hedges LV eds. The handbook of research synthesis. Russell Sage Foundation, 1991: 231-44.